Boryung

Product family built on Kanarb (fimasartan), launched in 2011 as Korea's first ARB-class antihypertensive new drug, and its combinations; in June 2026 it added Kanarb Jet, combining fimasartan, atorvastatin and ezetimibe.

The oncology drug Taxotere (docetaxel), whose global business rights were acquired from Sanofi, covering 19 countries.

Combination of fimasartan and dapagliflozin for adults with both hypertension and type 2 diabetes, in a Phase 3 trial with 276 subjects in Korea and abroad.

Production site with cytotoxic oncology manufacturing capability, to which the company plans to move Taxotere production after technology transfer and country-by-country approvals.

Completed the acquisition of the global business rights to the oncology drug Taxotere from Sanofi.

Launched Kanarb Jet, a three-ingredient combination of fimasartan, atorvastatin and ezetimibe, adding a product for patients treated for both hypertension and dyslipidemia.

Signed a seven-year Taxotere supply agreement with Yifan Pharmaceutical of China worth about KRW 383.7 billion (USD 277.14 million), including annual minimum purchase obligations.

Reported cumulative sales of KRW 849.4 billion for the first three quarters of 2026, with oncology sales of KRW 221.4 billion, up 24% year on year.